期刊文献+

冠脉介入术支架内血栓的危险因素和预防策略 被引量:7

Risk Factors and Prevention Strategies of Stent Thrombosis
下载PDF
导出
摘要 支架内血栓形成是经皮冠状动脉介入治疗罕见但极为严重的并发症,常导致患者心肌梗死和死亡。其危险因素包括抗血小板治疗、支架因素、介入操作因素、患者及病变因素等。预防的关键在于积极防治上述危险因素,主要包括延长抗血小板治疗疗程、选择合适的支架类型和操作技术、开发新型支架和抗血小板药物,同时注意冠心病二级预防。 Stent thrombosis, a rare but potentially lethal complication of percutaneous coronary intervention, is associated with high rates of death and myocardial infarction. The mechanisms are multifactorial, and involve factors related to the stent, anti--platelet therapy, the coronary lesion, the patient and the technique. Prevention strategies focus on preventing and treating these risk factors,mainly including the extension of anti--platelet therapy, selecting the appropriate stent type and operating techniques, development of new stent and anti--platelet drugs, paying attention to secondary prevention of coronary heart disease.
出处 《医学与哲学(B)》 2010年第3期23-24,35,共3页 Medicine & Philosophy(B)
关键词 支架内血栓 危险因素 预防策略 stent thrombosis, risk factors, prevention strategies
  • 相关文献

参考文献1

  • 1Eric L Eisenstein, DBA,Kevin J. Anstrom, PhD,David F. Kong, MD,Linda K. Shaw, MS,Robert H. Tuttle, MSPH,Daniel B. Mark, MD, MPH,Judith M. Kramer, MD, MS,Robert A. Harrington, MD,David B. Matchar, MD,David E. Kandzari, MD 1,Eric D. Peterson, MD, MPH,Kevin A. Schulman, MD,Robert M. Califf, MD,李呈亿(译),David E. Kandzari, MD.氯吡格雷的使用与药物洗脱支架植入后远期临床结果[J].美国医学会杂志(中文版),2007,26(3):131-139. 被引量:59

二级参考文献28

  • 1Moses JW, Leon MB, Poprna JJ, et al. Sirolimus-eluting s-tents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003,349:1315-1323.
  • 2Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-Ⅳ trial. Circulation. 2004;109:1942 - 1947.
  • 3Moses JW. CYPHER trials. Presented at: American College of Cardiology Annual Scientific Session 2006 Rapid News Summaries; March 11-14, 2006; Atlanta, Ga. http://www.cardiosource.com /rapid newssu mmaries/index.asp?EID=22 &DoW=Mon&SumID=165. Accessed July 1, 2006.
  • 4Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report fiom the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006; 113:e85-e151.
  • 5Leon MB, Bairn DS, Popma J J, et al; Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenUng. N Engl J Med. 1998;339: 1665-1671.
  • 6Cutlip DE, Balm DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001, 103:1967-1971.
  • 7Berger PB, Mahaffey KW, Meier S J, et al. Safety and efficacy of only 2 weeks of ticlopicline therapy in patients at increased dsk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. Am Heart J. 2002;143:841-846.
  • 8Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
  • 9Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug- eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803-2809.
  • 10Regar E, Lemos PA, Saia F, et al. Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients. Am J Cardiol. 2004;93:1271- 1275.

共引文献58

同被引文献114

引证文献7

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部